Compare HXHX & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HXHX | XBIO |
|---|---|---|
| Founded | 2003 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 4.7M |
| IPO Year | 2022 | 2011 |
| Metric | HXHX | XBIO |
|---|---|---|
| Price | $0.19 | $1.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 22.2K |
| Earning Date | 11-03-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,976,411.00 |
| Revenue This Year | N/A | $2.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.96 | ★ N/A |
| Revenue Growth | N/A | ★ 19.04 |
| 52 Week Low | $0.19 | $1.85 |
| 52 Week High | $1.36 | $4.94 |
| Indicator | HXHX | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 20.09 | 32.29 |
| Support Level | N/A | N/A |
| Resistance Level | $0.56 | $2.53 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 3.75 | 11.03 |
Haoxin Holdings Ltd is a China-based logistics company engaged in temperature-controlled transportation and urban delivery services. The company provides cold chain logistics, freight forwarding, and related transportation services for goods, including new energy materials, electronic products, pharmaceuticals, meat, fruits, and vegetables. Its principal revenue streams are temperature-controlled truckload services and urban delivery services.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.